Overview

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

Status:
Terminated

Trial end date:
2018-09-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Collaborator:

Zinfandel Pharmaceuticals Inc.

Treatments:

Pioglitazone